The body is unable to repair and regenerate large area bone defects. Moreover, the repair capacity of articular cartilage is very limited. There has long been a lack of effective treatments for osteochondral lesions. The engineered tissue with biphase synthetic for osteochondral repair has become one of the hot research fields over the past few years. In this study, an integrated biomanufacturing platform was constructed with bone marrow mesenchymal stem cells (BMSCs)/porous tantalum (pTa) associated with chondrocytes/collagen membranes (CM) to repair large osteochondral defects in load-bearing areas of goats. Twenty-four goats with a large osteochondral defect in the femoral heads of the left hind legs were randomly divided into three groups: eight were treated with chondrocytes/CM-BMSCs/pTa, eight were treated with pure CM-pTa composite, and the other eight goats were untreated. The repair effect was assessed by X-ray, gross observation, and histomorphology for 16 weeks after the operation. In addition, the biocompatibility of chondrocytes/CM-BMSCs/pTa was observed by flow cytometry, CCK8, immunocytochemistry, and Q-PCR. The characteristics of the chondrocytes/CM-BMSCs/pTa were evaluated using both scanning electron microscopy and mechanical testing machine. The integrated repair material consists of pTa, injectable fibrin sealant, and CM promoted adhesion and growth of BMSCs and chondrocytes. pTa played an important role in promoting the differentiation of BMSCs into osteoblasts. Three-dimensional CM maintained the phenotype of chondrocytes successfully and expressed chondrogenic genes highly. The in vivo study showed that after 16 weeks from implantation, osteochondral defects in almost half of the femoral heads had been successfully repaired by BMSC-loaded pTa associated with biomimetic 3D collagen-based scaffold. The chondrocytes/CM-BMSCs/pTa demonstrated significant therapeutic efficacy in goat models of large osteochondral defect. This provides a novel therapeutic strategy for large osteochondral lesions in load-bearing areas caused by severe injury, necrosis, infection, degeneration, and tumor resection with a high profile of safety, effectiveness, and simplicity.
7 March 2023 in Frontiers in Bioengineering and Biotechnology
Introduction: Developing a culture system that can effectively maintain chondrocyte phenotype and functionalization is a promising strategy for cartilage repair.Methods: An alginate/collagen (ALG/COL) hybrid hydrogel using different guluronate/mannuronate acid ratio (G/M ratio) of alginates (a G/M ratio of 64/36 and a G/M ratio of 34/66) with collagen was developed. The effects of G/M ratios on the properties of hydrogels and their effects on the chondrocytes behaviors were evaluated.Results: The results showed that the mechanical stiffness of the hydrogel was significantly affected by the G/M ratios of alginate. Chondrocytes cultured on Mid-G/M hydrogels exhibited better viability and phenotype preservation. Moreover, RT-qPCR analysis showed that the expression of cartilage-specific genes, including SOX9, COL2, and aggrecan was increased while the expression of RAC and ROCK1 was decreased in chondrocytes cultured on Mid-G/M hydrogels.Conclusion: These findings demonstrated that Mid-G/M hydrogels provided suitable matrix conditions for cultivating chondrocytes and may be useful in cartilage tissue engineering. More importantly, the results indicated the importance of taking alginate G/M ratios into account when designing alginate-based composite materials for cartilage tissue engineering.
2 August 2024 in International Journal of Biological Macromolecules
Matrigel-based hydrogel microspheres fabricated using microfluidic technology have emerged as promising carriers for tumor organoid modeling. However, their intrinsic low stiffness limits their ability to mimic the mechanical properties of the native tumor microenvironment. To overcome this limitation, we developed an interpenetrating polymer network by incorporating alginate into Matrigel, yielding alginate-Matrigel (AM) composite hydrogel microspheres with tunable stiffness via droplet microfluidics technique. Additionally, to eliminate the cytotoxic effects associated with acidic conditions in alginate-based droplet microfluidics process by acid-driven gelation methods, a novel external gelation strategy was designed. A Ca2+ preloaded gelatin substrate (contact angle > 80°) was employed to receive AM droplets, enabling rapid in situ crosslinking and solidification. Notably, cells encapsulated within AM microspheres exhibited high viability throughout the gelation process, and the resulting microspheres displayed excellent sphericity and structural uniformity. The entire workflow—spanning droplet formation, allocation, gelation, culture, and drug testing—was integrated into a streamlined single-step process optimized for high-throughput screening. The stiffness significantly increased over 7-fold, elevating from 0.6 kPa in Matrigel microsphere to 5.0 kPa in AM microsphere. Compared to Matrigel-only microspheres, both patient-derived tumor organoids and cell line spheroids in AM microspheres demonstrate enhanced chemoresistance, as indicated by elevated IC50 values. Taken together, this simple, biocompatible, and reproducible fabrication strategy offers a powerful platform for organoid modeling, drug screening, and patient-relevant drug testing.
10 June 2026 in Frontiers in Cardiovascular Medicine
Background: Breast cancer is the most common female malignancy globally. With improved survival, cardiovascular diseases have become a key morbidity source due to shared cardiometabolic risk factors (e.g., dyslipidemia). While cardiovascular risk varies by breast cancer molecular subtype, baseline pre-treatment cardiovascular comorbidities and lipid abnormalities remain undercharacterized. We aimed to describe their prevalence and subtype-specific patterns in newly diagnosed patients. Methods: This single-center retrospective cohort study included 5,246 Chinese women with newly diagnosed breast cancer (2014–2024), with all data collected before anticancer therapy. Patients were stratified into five molecular subtypes. Baseline cardiovascular comorbidities, tumor features, and serum lipids were analyzed using chi-square tests, ANOVA, and multivariable logistic regression. Results: Age, cardiovascular comorbidities, electrocardiographic abnormalities and lipid profiles differed significantly across subtypes. Overall dyslipidemia prevalence was 54.1%, highest in Luminal A and lowest in Luminal B (HER2 negative). Intravascular tumor thrombus was independently associated with dyslipidemia in all subtypes, with the strongest association in triple-negative breast cancer. Lymph node metastasis correlated with dyslipidemia only in Luminal B subtypes, and several factors showed subtype-specific associations. Conclusions: Dyslipidemia is common at baseline in treatment-naive breast cancer patients and varies by molecular subtype. Tumor-related features, particularly intravascular tumor thrombus, are consistently associated with dyslipidemia. Early lipid screening and cardiovascular risk assessment may optimize cardio-oncology care.